Literature DB >> 31911858

Compensatory upregulation of aldo-keto reductase 1B10 to protect hepatocytes against oxidative stress during hepatocarcinogenesis.

Yongzhen Liu1, Jing Zhang1, Hui Liu1, Guiwen Guan1, Ting Zhang1, Leijie Wang1, Xuewei Qi1, Huiling Zheng1, Chia-Chen Chen1, Jia Liu1, Deliang Cao2, Fengmin Lu3, Xiangmei Chen1.   

Abstract

Aldo-keto reductase 1B10 (AKR1B10), a member of aldo-keto reductase superfamily, contributes to detoxification of xenobiotics and metabolization of physiological substrates. Although increased expression of AKR1B10 was found in hepatocellular carcinoma (HCC), the role of AKR1B10 in the development of HCC remains unclear. This study aims to illustrate the role of AKR1B10 in hepatocarcinogenesis based on its intrinsic oxidoreduction abilities. HCC cell lines with AKR1B10 overexpression or knockdown were treated with doxorubicin or hydrogen peroxide to determinate the influence of aberrant AKR1B10 expression on cells' response to oxidative stress. Using Akr1b8 (the ortholog of human AKR1B10) knockout mice, diethylnitrosamine (DEN) induced liver injury, chronic inflammation and hepatocarcinogenesis were explored. Clinically, the pattern of serum AKR1B10 relevant to disease progression was investigated in a patient cohort with chronic hepatitis B (n=30), liver cirrhosis (n=30) and HCC (n=40). AKR1B10 expression in HCC tissues was analyzed using both the TCGA database (n=371) and our collected HCC samples (n=67). AKR1B10 overexpression reduced hepatocyte injury while AKR1B10 knockdown augmented reactive oxygen species (ROS) accumulation and apoptotic cell death. Consistently, Akr1b8 deficiency in mice promoted DEN-induced hepatocyte damage and liver inflammation characterized by increased phospho-H2AX, serum alanine aminotransferase, interleukin-6 and tumor necrosis factor alpha level, myeloid cell infiltration and led to more severe hepatocarcinogenesis and metastasis compared with wild type mice due to significant alteration on detoxification and oxidoreduction. AKR1B10 was compensatory expressed and gradually upregulated in the process of liver disease progression in HCC and increased oxidative stress upregulated AKR1B10 through NRF2. Our results here suggested that through oxidoreduction and detoxification, AKR1B10 played an important role in protecting hepatocytes from damage induced by ROS. Deficiency of AKR1B10 might accelerate hepatotoxin and inflammation-associated hepatocarcinogenesis. AKR1B10 expression elevation in HCC could be a result of compensatory upregulation, rather than a driver of malignant transformation during the development of HCC. AJCR
Copyright © 2019.

Entities:  

Keywords:  AKR1B10; Hepatocarcinogenesis; ROS; oxidoreduction

Year:  2019        PMID: 31911858      PMCID: PMC6943354     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  49 in total

1.  Identification and characterization of a novel human aldose reductase-like gene.

Authors:  D Cao; S T Fan; S S Chung
Journal:  J Biol Chem       Date:  1998-05-08       Impact factor: 5.157

2.  Aldose reductase functions as a detoxification system for lipid peroxidation products in vasculitis.

Authors:  H L Rittner; V Hafner; P A Klimiuk; L I Szweda; J J Goronzy; C M Weyand
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

3.  Murine aldo-keto reductase family 1 subfamily B: identification of AKR1B8 as an ortholog of human AKR1B10.

Authors:  Amit Joshi; Sandeep Rajput; Chun Wang; Jun Ma; Deliang Cao
Journal:  Biol Chem       Date:  2010-12       Impact factor: 3.915

4.  BACH1 Stabilization by Antioxidants Stimulates Lung Cancer Metastasis.

Authors:  Clotilde Wiel; Kristell Le Gal; Mohamed X Ibrahim; Chowdhury Arif Jahangir; Muhammad Kashif; Haidong Yao; Dorian V Ziegler; Xiufeng Xu; Tanushree Ghosh; Tanmoy Mondal; Chandrasekhar Kanduri; Per Lindahl; Volkan I Sayin; Martin O Bergo
Journal:  Cell       Date:  2019-06-27       Impact factor: 41.582

Review 5.  Molecular events associated with reactive oxygen species and cell cycle progression in mammalian cells.

Authors:  Johannes Boonstra; Jan Andries Post
Journal:  Gene       Date:  2004-08-04       Impact factor: 3.688

6.  Role of human aldo-keto-reductase AKR1B10 in the protection against toxic aldehydes.

Authors:  Hans-Jörg Martin; Edmund Maser
Journal:  Chem Biol Interact       Date:  2008-11-01       Impact factor: 5.192

Review 7.  New anthracycline antitumor antibiotics.

Authors:  F M Muggia; M D Green
Journal:  Crit Rev Oncol Hematol       Date:  1991       Impact factor: 6.312

8.  Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma.

Authors:  Yeon Tae Chung; Kristina A Matkowskyj; Haonan Li; Han Bai; Wanying Zhang; Ming-Sound Tsao; Jie Liao; Guang-Yu Yang
Journal:  Mod Pathol       Date:  2012-01-06       Impact factor: 7.842

9.  JASPAR 2018: update of the open-access database of transcription factor binding profiles and its web framework.

Authors:  Aziz Khan; Oriol Fornes; Arnaud Stigliani; Marius Gheorghe; Jaime A Castro-Mondragon; Robin van der Lee; Adrien Bessy; Jeanne Chèneby; Shubhada R Kulkarni; Ge Tan; Damir Baranasic; David J Arenillas; Albin Sandelin; Klaas Vandepoele; Boris Lenhard; Benoît Ballester; Wyeth W Wasserman; François Parcy; Anthony Mathelier
Journal:  Nucleic Acids Res       Date:  2018-01-04       Impact factor: 16.971

Review 10.  Oxidative stress, a trigger of hepatitis C and B virus-induced liver carcinogenesis.

Authors:  Alexander V Ivanov; Vladimir T Valuev-Elliston; Daria A Tyurina; Olga N Ivanova; Sergey N Kochetkov; Birke Bartosch; Maria G Isaguliants
Journal:  Oncotarget       Date:  2017-01-17
View more
  5 in total

1.  Regulation Network and Prognostic Significance of Aldo-Keto Reductase (AKR) Superfamily Genes in Hepatocellular Carcinoma.

Authors:  Tianxing Dai; Linsen Ye; Haoyuan Yu; Kun Li; Jing Li; Rongqiang Liu; Xu Lu; Mingbin Deng; Rong Li; Wei Liu; Yang Yang; Guoying Wang
Journal:  J Hepatocell Carcinoma       Date:  2021-08-30

Review 2.  Aldo Keto Reductases AKR1B1 and AKR1B10 in Cancer: Molecular Mechanisms and Signaling Networks.

Authors:  Sreeparna Banerjee
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  E2F1-mediated AUF1 upregulation promotes HCC development and enhances drug resistance via stabilization of AKR1B10.

Authors:  Ting Zhang; Guiwen Guan; Jing Zhang; Huiling Zheng; Deyao Li; Wengong Wang; Fengmin Lu; Xiangmei Chen
Journal:  Cancer Sci       Date:  2022-02-17       Impact factor: 6.716

4.  A novel diagnostic four-gene signature for hepatocellular carcinoma based on artificial neural network: Development, validation, and drug screening.

Authors:  Min Chen; Guang-Bo Wu; Zhi-Wen Xie; Dan-Li Shi; Meng Luo
Journal:  Front Genet       Date:  2022-09-28       Impact factor: 4.772

Review 5.  The Role of AKR1B10 in Physiology and Pathophysiology.

Authors:  Satoshi Endo; Toshiyuki Matsunaga; Toru Nishinaka
Journal:  Metabolites       Date:  2021-05-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.